 |
年間契約型情報サービス
Drug Delivery Insight |
||||||
| 発行 | Espicom Business Intelligence | 商品コード | 8302 | ||||
| 出版日 | 年22回 年間契約型情報サービス | ページ情報 | 英文 16 Pages | ||||
| 価格 |
|
||||||
| Drug Delivery Insight Drug Delivery Insight | ||
| 出版日: 年22回 年間契約型情報サービス | ページ情報: 英文 16 Pages |
|
 |
医療市場の調査会社として定評を得ておりますEspicom Business Intelligence（本社：英国）ではドラッグデリバリー市場の最新情報を収めた英文ニューズレター"Drug Delivery Insight"を年間22回発行しております。 当ニューズレターは、注射器、注入ポンプ、経皮デリバリーからスロー/コントロール・リリース、埋め込み式、バイオテクノロジーによる方法迄世界のあらゆるドラッグデリバリー技術を網羅しており、企業や製品の動向、提携や協力の動き、研究活動を常に注視して、急速に拡大しておりますドラッグデリバリー市場について、下記項目ごとに詳細かつ最新の情報をご提供致しております。
|
BMI View: The use of enduring drug-delivery implants will increase in the long-term as they provide a solution to overcome the prevalent issues of non-compliance, particularly as the burden from chronic diseases increases. However, short-term pressures from cyber security, risks from leakages, and a lack of infrastructure to cater for the implementation will limit near-term uptake.
1 Compliance Burden Key Driver For Drug-Delivery Implants
Corporate News
3 Agreements
3 Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales
5 Vectura/Janssen Sign Deal To Develop Anti-Inflammatory Therapy
5 Seattle Genetics/BMS Enter Clinical Trial Collaboration For Adcetris/Opdivo
5 Vect-Horus/Sanofi Enter Collaboration For Neurodegenerative Diseases
5 Corporate Activities
5 Hospira Unveils Progress On Global Device Strategy
6 BioLight Invests In Newly-Formed Ophthalmic Company
Product News
6 Product Approvals
6 FDA Clears t:flex Insulin Pump With Expanded Reservoir
6 FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients
6 La Fenice Insulin Pump Gains Re-Registration Approval In China
7 Flowonix Gains Supplemental PMA For Next-Generation Intrathecal Infusion Device
R&D
7 Medical Devices Appetite Growing For 3D Printing
8 Enrolment Begins In Tyrx Absorbable Antibacterial Envelope Trial For CIEDs Infections
8 Novartis Reports Positive Results From Phase III COPD Studies
9 First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint
10 Photocure Concludes End Of Phase II Status For Cevira In US
10 Patents
10 NSAID Market Set To Welcome Encapsulated Equivalents
11 Oramed Granted Patent In Israel Covering Exenatide
11 Actavis Challenges US Abstral Patents
11 Regulatory Filings
11 Sacituzumab Govitecan Gains FDA Fast Track Designation For TNBC
12 LEO Submits NDA For Calcipotriene+Betamethasone Aerosol Foam In Plaque Psoriasis
12 Neos Submits NDA For Methylphenidate XR-ODT For ADHD
